| First Author | Marazuela P | Year | 2022 |
| Journal | Int J Mol Sci | Volume | 23 |
| Issue | 9 | PubMed ID | 35563362 |
| Mgi Jnum | J:348540 | Mgi Id | MGI:7279991 |
| Doi | 10.3390/ijms23094972 | Citation | Marazuela P, et al. (2022) Impact of Cerebral Amyloid Angiopathy in Two Transgenic Mouse Models of Cerebral beta-Amyloidosis: A Neuropathological Study. Int J Mol Sci 23(9) |
| abstractText | The pathological accumulation of parenchymal and vascular amyloid-beta (Abeta) are the main hallmarks of Alzheimer's disease (AD) and Cerebral Amyloid Angiopathy (CAA), respectively. Emerging evidence raises an important contribution of vascular dysfunction in AD pathology that could partially explain the failure of anti-Abeta therapies in this field. Transgenic mice models of cerebral beta-amyloidosis are essential to a better understanding of the mechanisms underlying amyloid accumulation in the cerebrovasculature and its interactions with neuritic plaque deposition. Here, our main objective was to evaluate the progression of both parenchymal and vascular deposition in APP23 and 5xFAD transgenic mice in relation to age and sex. We first showed a significant age-dependent accumulation of extracellular Abeta deposits in both transgenic models, with a greater increase in APP23 females. We confirmed that CAA pathology was more prominent in the APP23 mice, demonstrating a higher progression of Abeta-positive vessels with age, but not linked to sex, and detecting a pronounced burden of cerebral microbleeds (cMBs) by magnetic resonance imaging (MRI). In contrast, 5xFAD mice did not present CAA, as shown by the negligible Abeta presence in cerebral vessels and the occurrence of occasional cMBs comparable to WT mice. In conclusion, the APP23 mouse model is an interesting tool to study the overlap between vascular and parenchymal Abeta deposition and to evaluate future disease-modifying therapy before its translation to the clinic. |
